#	Pagina
attuale pagina	/open-h2020/projects/193761/index.html

Opendata, web and dolomites

CannaPreg

Development of pregnenolone derivatives as allosteric inhibitors of CB1 cannabinoid receptors for the treatment of schizophrenia and psychotic syndromes

Total Cost €

EC-Contrib. €

Partnership

Views

CannaPreg project word cloud

Explore the words cloud of the CannaPreg project. It provides you a very rough idea of what is the project "CannaPreg" about.

brain functions excessive competitiveness acts clear signalling found etiopathogenesis basic poc compound commercial sought establishing bridging scientific benefits cb1 receptors industry therapeutic derivative pathological derivatives societal compounds sativa plays decrease spirit drugs activation stg market erc inhibitor syndromes direct idea later endogenous stages human limiting class labile plant lipid ameliorated signal innovative participate cannabinoid blocking cannabinoids successful allosteric synthetic stable will additional medical psychotic induce inhibitors schizophrenia economical receptor cannabis inhibition pregnenolone treatment antagonist

Project "CannaPreg" data sheet

The following table provides information about the project.

Coordinator	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2014-PoC
Funding Scheme	ERC-POC
Starting year	2015
Duration (year-month-day)	from 2015-01-01 to 2016-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	150˙000.00

Map

Project objective

Excessive activation of the cannabinoid type-1 receptor (CB1) in the brain by synthetic, endogenous or plant-derived (cannabis sativa) cannabinoids can lead to pathological states, which could be ameliorated by blocking receptor signalling. However, due to the large number of functions involving the CB1 receptor, direct CB1 antagonist drugs induce side effects limiting their therapeutic use. During the ERC-StG funded project, we found that a particular endogenous and labile lipid compound, pregnenolone, acts as an allosteric and signal-specific inhibitor of CB1 receptors in the brain. Thus, stable pregnenolone-derivative drugs have been produced to exploit the therapeutic potential of allosteric inhibition of CB1 receptor signalling, which can be used to decrease pathological over-activation of CB1 receptors. One clear pathological state where over-activation of CB1 receptors plays a key role is schizophrenia and psychotic syndromes. Indeed, cannabis and synthetic cannabinoids can induce psychotic states and excessive CB1 receptor signalling has been proposed to participate in the etiopathogenesis of human schizophrenia. Thus, the present project aims at establishing the innovative and commercial potential of this new class of drugs, stable derivatives of pregnenolone, as allosteric inhibitors of the CB1 receptor for the treatment of psychotic syndromes. The following issues will be addressed: 1. Technical activities will identify the compounds with the best therapeutic potential. 2. Market studies will determine the potential competitiveness of these compounds. 3. Additional industry partnerships will be sought for later stages of commercial development. By covering these essential steps bridging a scientific idea from basic research to therapeutic applications, the present project is fully integrated in the spirit of the ERC PoC program and, if successful, will provide key medical, economical and societal benefits to Europe.

Publications

List of publications.
year	authors and title	journal	last update
2016	J.F. Oliveira da Cruz, L.M. Robin, F. Drago, G. Marsicano, M. Metna-Laurent Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse published pages: 35-42, ISSN: 0306-4522, DOI: 10.1016/j.neuroscience.2015.05.002	Neuroscience 323	2019-07-23
2015	Edgar Soria-GÃ³mez, Arnau Busquets-Garcia, Fei Hu, Amine Mehidi, Astrid Cannich, Liza Roux, Ines Louit, Lucille Alonso, Theresa Wiesner, Francois Georges, DaniÃ¨le Verrier, Peggy Vincent, Guillaume Ferreira, Minmin Luo, Giovanni Marsicano Habenular CB1 Receptors Control the Expression of Aversive Memories published pages: 306-313, ISSN: 0896-6273, DOI: 10.1016/j.neuron.2015.08.035	Neuron 88/2	2019-07-23
2016	Arnau Busquets Garcia, Edgar Soria-Gomez, Luigi Bellocchio, Giovanni Marsicano Cannabinoid receptor type-1: breaking the dogmas published pages: 990, ISSN: 2046-1402, DOI: 10.12688/f1000research.8245.1	F1000Research 5	2019-07-23
2016	Ana GutiÃ©rrez-RodrÃguez, Nagore Puente, Izaskun Elezgarai, Sabine Ruehle, Beat Lutz, Leire Reguero, Inmaculada Gerrikagoitia, Giovanni Marsicano, Pedro Grandes Anatomical characterization of the cannabinoid CB 1 receptor in cell-type-specific mutant mouse rescue models published pages: , ISSN: 0021-9967, DOI: 10.1002/cne.24066	Journal of Comparative Neurology	2019-07-23
2015	Beat Lutz, Giovanni Marsicano, Rafael Maldonado, Cecilia J. Hillard The endocannabinoid system in guarding against fear, anxiety and stress published pages: 705-718, ISSN: 1471-003X, DOI: 10.1038/nrn4036	Nature Reviews Neuroscience 16/12	2019-07-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANNAPREG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANNAPREG" are provided by the European Opendata Portal: CORDIS opendata.